COVID-19: China Sinopharm Vaccine: “Trial Discontinuation” in Peru
-Participant’s arm is paralyzed-
China: Sinopharm
Peruvian National Health Institute:
Currently, clinical trials of Chinese state-owned pharmaceuticals and vaccines are underway in Peru.
The Peruvian National Health Center suddenly suspended the trial of the “Sinopharm” COVID-19 vaccine.
On December 11th (local time), the reason was clarified.
Agence France-Presse:
The suspension of this clinical trial is due to one participant being unable to move his arm due to “Guillain-Barré syndrome”.
wowkorea.jp
http://www.wowkorea.jp/news/Korea/2020/1212/10280470.html
Peru suspends clinical trials of Chinese COVID-19 vaccine
LIMA: Peru
has temporarily suspended clinical trials of a COVID-19 vaccine made by Chinese drug giant Sinopharm after detecting neurological problems in one of its test volunteers.
The National Institute of Health
said on Friday (Dec 11) that it had decided to interrupt the trial after a volunteer had difficulty moving their arms, according to local media.
Several days ago
we signalled, as we are required, to the regulatory authorities that one of our participants (in trials) presented neurological symptoms
which could correspond to a condition called Guillain-Barre syndrome,” said chief researcher German Malaga in comments to the press.
Guillain-Barre syndrome
is a rare and non-contagious disorder which affects the movement of the arms and legs.
Peru declared
a temporary health emergency in five regions in June last year following multiple cases.
CNA
Peru halts Chinese coronavirus vaccine trials after volunteer develops neurological problems